A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study

<table> (a) Primary endpoint: percentage of patients achieving target LDL-C (&lt;2.0 mmol/L) at 6 weeks (b) Percentage of patients achieving target LDL-C (&lt;2.0 mmol/L) at 12 weeks.</table>

Advances in Preventive Medicine

fig3

Figure 3

Figure 3: A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study 

Figure 3 | A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study 